Thoracic (Lung)
Thoracic (Lung)
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
10
Clinical Trials
Thoracic (Lung)
Phase I/II
Enrolling
nct/study# NCT06362252 / DS7300-189
A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd), A B7-H3 ANTIBODY-DRUG CONJUGATE (ADC), IN COMBINATION WITH ATEZOLIZUMAB WITH OR WITHOUT CARBOPLATIN AS FIRST-LINE INDUCTION OR MAINTENANCE, IN SUBJECTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Learn More
Thoracic (Lung)
Pilot
Enrolling
nct/study# N/A / EBCPILOTPRO2020-0258
Evaluation of Exhaled Breath Condensates as a Remote Source of Lung Cancer Biomarkers
Learn More
Thoracic (Lung)
Phase II
Enrolling
nct/study# NCT05715229 / G360-IIT
A Multi-Center Phase II Randomized Trial of Immunotherapy versus Chemoimmunotherapy Guided by Circulating Tumor DNA Based Molecular Response on Patients with Metastatic NSCLC
Learn More
Thoracic (Lung)
Phase II
Enrolling
nct/study# NCT04958811 / ML42919
A Phase II Open-label Multi-cohort Study Evaluating the Efficacy of Tiragolumab with Atezolizumab plus Bevacizumab in Previously-Treated Advanced Non- squamous NSCLC
Learn More
Thoracic (Lung)
N/A
Enrolling
nct/study# NCT04535557 / MOBO-IZ2966-1
An expanded access program for mobocertinib in Non Small Cell Lung Cancer exon20 insertion mutation patients
Learn More
Thoracic (Lung)
Phase II
Enrolling
nct/study# NCT04410796 / MSK-20-011
Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.